At Avalon AI, we take a structural MRI scan and predict when a patient with Mild Cognitive Impairment (MCI) will transition to Dementia. Using it, we can predict with 75% accuracy whether a patient will transition or stay stable within a year. Our aim is two-fold: Firstly, we want to accelerate the search for effective treatments for Dementia by helping clinical trials enroll only the patients that are likely to deteriorate soon. Secondly, we want to use our technology to help personalize medical treatment to deliver effective health care tailored to each individual.
